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and presence of diabetes or hypertension are all as-
sociated with increased 30-day mortality after CABG. 
CONCLUSION: The incidence of major adverse events
in CABG patients varies widely across different studies
and patient populations. This heterogeneity must be con-
trolled when using the literature to benchmark safety.
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Current data are limited regarding the effects of statins in
the naturalistic setting of clinical practice.
OBJECTIVES: This study sought to determine the effects
of statins on the lipid proﬁle and target LDL-cholesterol
(LDL-C) attainment in this setting. 
METHODS: Patients newly initiated on atorvastatin, 
ﬂuvastatin, pravastatin, or simvastatin from 1/99 to 6/99
were retrospectively identiﬁed from a southeastern U.S.
health plan database. A parallel design incorporated four
study arms based on the statin prescribed. Exclusion 
criteria included statin therapy in the prior 6 months, less
than 90 days of statin therapy, switching of statin, use of
combination dyslipidemia therapy, or non-continuous
enrollment in the health plan. Changes in lipid subfrac-
tions and attainment of LDL-C goal based on NCEP ATP
II guidelines were evaluated with OLS and logistic regres-
sion techniques utilizing clinically relevant covariates.
RESULTS: A total of 2,429 patients (age = 62 ± 13 years,
47.8% male) were identiﬁed. Comorbidities included
73% hypertension, 24% diabetes, and 34% atheroscle-
rotic vascular disease. Median duration of statin therapy
was 19.4 months. Patients receiving atorvastatin had sig-
niﬁcantly greater mean absolute (and percentage) reduc-
tions in LDL-C and triglycerides compared to the other
statins in both the unadjusted and adjusted results (all 
p < 0.05 vs. atorvastatin). Differences in HDL-cholesterol
(HDL-C) were small, however, a statistically signiﬁcant
increase was observed with simvastatin compared to 
atorvastatin (p < 0.05). Also, a signiﬁcantly greater per-
centage (unadjusted, adjusted) of patients reached their
NCEP LDL-C goal on atorvastatin (74.0%, 73.0%) com-
pared with ﬂuvastatin (52.0%, 51.0%), pravastatin
(58.3%, 56.4%) and simvastatin (69.0%, 69.4%), and
atorvastatin patients reached goal faster than the other
statins (median: 184 days vs. 215–357 days, all p < 0.05
vs. atorvastatin). 
CONCLUSION: Patients prescribed atorvastatin had 
statistically signiﬁcant improvements in LDL-C and
triglycerides, though not in HDL-C, compared to those
prescribed other statins. In addition, atorvastatin patients
attained LDL-C goal more often and in a shorter 
timeframe.
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OBJECTIVES: The beneﬁts of aggressive lipid-lowering
(L-L) therapy among patients with an elevated risk of
coronary heart disease (CHD) are well established, but
longitudinal data from clinical practice are limited. Our
objective was to assess trends in the rate of cholesterol
goal attainment (based on NCEP criteria) among moder-
ate- and high-risk patients in a managed care setting. 
METHODS: A retrospective cohort design was employed
using linked pharmacy claims, medical claims, and clini-
cal laboratory data from members of a Northeastern US
group model HMO. The study cohort included patients
55+ years of age who were newly treated with L-L drug
therapy between 1995 and 1998, had an LDL-C value
over 160mg/dL within 90 days prior to treatment, and
had no history of CHD but at least one CHD risk factor
other than age. The duration of follow-up was 1 year.
RESULTS: A total of 1044 patients were identiﬁed. The
average age was 68 years and 41% were male. The mean
baseline LDL-C level was 197mg/dL. Most patients
(86%) began treatment with a statin, and adherence
(evaluated by “covered days”) averaged 61%. The mean
decline in LDL-C was 25%. Target LDL-C levels were
reached by 34% of this population. The rate of LDL-C
goal attainment increased from 18% in the 1995 cohort
to 46% in the 1998 cohort. The likelihood of reaching
goal was positively associated with cohort year (P < 0.01),
male gender (P = 0.05), and beginning treatment with a
statin (P = 0.04) and negatively associated with initial
LDL-C level (P < 0.01). Age and the number of risk
factors were not associated with goal attainment.
CONCLUSIONS: In this primary prevention population,
cholesterol management improved substantially over
time. Nonetheless, most patients still did not achieve their
target LDL-C levels, indicating that further research is
required to identify steps for increasing the effectiveness
of cholesterol treatment.
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OBJECTIVES: Warfarin anticoagulation has been shown
to effectively decrease the rate of thromboembolism (TE),
with an associated increased rate of bleeding. Maximiz-
ing the beneﬁt and minimizing the risk depends on 
maintaining patients in a narrow therapeutic range for
prothrombin time (measured as INR); increased percent-
